Pfizer (PFE) Income from Non-Controlling Interests (2009 - 2026)

Pfizer (PFE) has reported Income from Non-Controlling Interests for 18 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 33.33% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $43.0 million (down 2.27% YoY), while the FY2025 annual figure was $41.0 million, up 32.26% from the prior year.
• Income from Non-Controlling Interests steadied at $8.0 million in Q1 2026 per PFE's latest filing, from $8.0 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $23.0 million in Q3 2024 and bottomed at $6.0 million in Q2 2022.
• Historically, Income from Non-Controlling Interests has averaged $10.2 million across 5 years, with a median of $8.0 million in 2024.
• Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests sank 76.92% — and 2025, when it jumped 157.14%.
• Pfizer's Income from Non-Controlling Interests stood at $6.0 million in 2022, then jumped by 50.0% to $9.0 million in 2023, then jumped by 155.56% to $23.0 million in 2024, then sank by 65.22% to $8.0 million in 2025, then changed by 0.0% to $8.0 million in 2026.
• Business Quant data shows PFE's Income from Non-Controlling Interests at $8.0 million in Q1 2026, $8.0 million in Q4 2025, and $9.0 million in Q3 2025.